Sosei Group has been notified today by its strategic alliance partner Novartis the company has submitted a valid Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for QVM149, a potential new inhaled combination therapy for asthma. The MAA filing, which was previously planned for Q4 2019, has triggered a US$2.5 million payment to Sosei Heptares from Novartis.
QVM149 is an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol acetate, glycopyrronium bromide and mometasone furoate (IND/GLY/MF), delivered with the dose-confirming Breezhaler® inhalation device. Glycopyrronium bromide and certain intellectual property relating to its use and formulation were exclusively licensed to Novartis in April 2005 by Sosei Heptares and Vectura Group. Novartis is responsible for the development and commercialization of QVM149.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
QVM149 is currently being investigated in Phase III/IIIb studies (IRIDIUM1 and ARGON2), which are expected to complete in Q3 2019.
"The acceptance of the MAA submission for QVM149 is an important milestone in the development of this novel, once daily, inhaled combination therapy for asthma patients,” Shinichi Tamura, Chairman, President and CEO of Sosei Heptares, said. “More than one-third of asthma patients have uncontrolled disease despite the availability of multiple therapies. With the filing of the MAA for approval in Europe, we are greatly looking forward to see QVM149 become available to patients and improve the lives of those with uncontrolled asthma."